Stocktoria
TELA Bio, Inc. TELA
TELA Bio, Inc. (TELA) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $80.3M at a -48.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.34 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.708 |
| Retained earnings / assets | -4.883 |
| EBIT / assets | -0.415 |
| Equity / liabilities | 0.084 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TELA | TELA Bio, Inc. | 3/9 | -13.97 | — | +15.8% |
| SGHT | Sight Sciences, Inc. | 5/9 | -5.95 | — | -3.1% |
| IRMD | IRADIMED CORP | 5/9 | 14.84 | 53.4 | +14.4% |
| DCTH | DELCATH SYSTEMS, INC. | 6/9 | 1.26 | 165.4 | +129.1% |
| RCEL | AVITA Medical, Inc. | 3/9 | — | — | +11.5% |
| LUNG | Pulmonx Corp | 3/9 | -11.04 | — | +8% |
| PDEX | PRO DEX INC | 6/9 | 8.16 | 21.9 | +23.7% |
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
FAQ
Is TELA financially healthy?
TELA Bio, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TELA pay a dividend?
No, TELA Bio, Inc. does not currently pay a dividend.
How profitable is TELA?
In FY2025, TELA Bio, Inc. had a net margin of -48.4% and a return on equity of -615.1%.
What is the analyst price target for TELA?
The average Wall-Street price target for TELA Bio, Inc. is $2.25, about 212.4% above the recent price, from 5 analysts.
Is TELA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on TELA Bio, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.